---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034975"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:22:53.802289+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026

## Summary
- ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.
- Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).
- Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.
- LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.
- LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025.

## SEC filing metadata
- accession: 0001628280-24-034975
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/0001628280-24-034975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/adc-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034975
- JSON: https://secwatch.observer/filing/0001628280-24-034975.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.